Glaucoma is a chronic, global disease and the leading cause of adult irreversible blindness. The patient population continues to grow, affecting more than 4 million people in the U.S. and approximately 60 million people worldwide.
Tissue-sparing MicroPulse therapy, which can be performed on the Cyclo G6 via the newly-patented MicroPulse P3 (MP3) probe, is designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma-dedicated laser along with a family of single use probes, as well as the newly patented MP3 disposable. The Cyclo G6 also offers repeatable and minimally invasive approaches which may slow the progress of the glaucoma.
"We have found that the MicroPulse P3 therapy has the potential to address a significant unmet need in reducing ocular pressure in patients with glaucoma without having to perform an incision," said
"The MicroPulse system for the treatment of glaucoma along with MicroPulse P3 disposable probes underscore our evolving razor, razorblade business model that focuses on the sale of follow-on disposables that address glaucoma at its early, middle and late stages of development," said
About MicroPulse Technology
MicroPulse is a tissue-sparing laser delivery therapy that works by electronically "chopping" the laser emission into trains of microsecond pulses. This enhances the physician's ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments.
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning its future marketing initiatives, including those matters related to the upcoming AAO Annual Meeting, trends in treatment and product adoption and usage, product plans and future product releases, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended
Logo - http://photos.prnewswire.com/prnh/20141001/149809
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/iridex-to-showcase-cyclo-g6-laser-system-equipped-with-micropulse-tissue-sparing-glaucoma-technology-at-american-academy-of-ophthalmology-aao-meeting-300176407.html
SOURCE
Company Contact, Will Moore, President & Chief Executive Officer, 650-940-4700, or Investor Relations Contact, Matt Clawson, Pure Communications, 949-370-8500, matt@purecommunicationsinc.com
